Danish firm Novo Nordisk A/S has begun first in man studies for its experimental insulin pill which  pill replace the routine injection for diabetics even as India's Biocon is completing its version of oral insulin for scheduled launch in next 18 months.

All the major pharmaceutical and biotech players as well as major CROs are making India their base for conducting global clinical trials